(C) Overexpression of PPT1 in both SH-p.wtCLN1 cells and cell lines harboring a missense mutation was confirmed by immunoblotting analysis. were predicted to be hampered
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
(C) Overexpression of PPT1 in both SH-p.wtCLN1 cells and cell lines harboring a missense mutation was confirmed by immunoblotting analysis. were predicted to be hampered